8-K: Lifeloc Reports Q3 2025 Results Amid SpinDetect Push

Lifeloc Technologies, Inc. announced its third quarter 2025 financial results, reporting increased revenue but a wider net loss driven by R&D investments in its SpinDetect drug analyzer.

Summary

• Net revenue for the third quarter of 2025 was $2.257 million, an 8% increase compared to $2.087 million in the third quarter of 2024.
• The company posted a quarterly net loss of $(263) thousand, or $(0.10) per diluted share, in Q3 2025, compared to a net loss of $(158) thousand, or $(0.06) per diluted share, in Q3 2024.
• For the first nine months of 2025, net revenues were $6.754 million, with a net loss of $(950) thousand, or $(0.35) per diluted share.
• This compares to nine-month 2024 net revenues of $6.628 million and a net loss of $(740) thousand, or $(0.30) per diluted share.
• Total gross margin decreased to 40.2% in Q3 2025 from 43.7% in Q3 2024, and to 40.6% for the first nine months of 2025 from 41.4% in 2024.
• The margin decline is attributed to general cost inflation and tariffs.
• Losses for the quarter and year-to-date were primarily caused by high research and development costs associated with commercializing the SpinDetect centrifugal drug analyzer.
• Cash and cash equivalents decreased to $685,097 as of September 30, 2025, from $1,243,746 at December 31, 2024.
• Total assets were $8,301,270 as of September 30, 2025, down from $8,724,769 at December 31, 2024.
• Total liabilities increased to $2,676,857 as of September 30, 2025, from $2,498,892 at December 31, 2024.
• Stockholders' equity decreased to $5,624,413 as of September 30, 2025, from $6,225,877 at December 31, 2024.

Sentiment

Score: 4

Explanation: While revenue increased and the SpinDetect drug analyzer shows promising technical progress and market potential, the company experienced a wider net loss, decreased gross margins due to inflation and tariffs, and a significant reduction in cash reserves. The explicit mention of needing additional financing for SpinDetect's commercialization highlights financial pressure.

Positives

• Quarterly net revenue increased by 8% to $2.257 million in Q3 2025 compared to Q3 2024.
• The core alcohol detection product line-up, including L-series LX9, LT7, FC-series devices, Easycal automated calibration station, and workplace Phoenix 6.0 BT and EV 30, continues to be strong and drives market penetration.
• The SpinDetect centrifugal drug analyzer platform has successfully detected multiple drug classes (delta-9-THC, cocaine, fentanyl, amphetamine, methamphetamine, morphine, MDMA, and benzodiazepines) in laboratory testing.
• SpinDetect results have been validated against gold-standard liquid chromatography-mass spectrometry (LCMS) testing of human samples, confirming real-world performance at detection limits of approximately 10 ng/ml.
• Beta testing of the SpinDetect oral-fluid analyzer, focused on delta-9-THC detection, is being initiated with a prototype reader and a signed beta-testing agreement.
• The company is exploring broader applications of its microfluidic technology beyond drug testing, including public health, food safety, and environmental testing.
• Lifeloc Technologies shares began trading on the OTCID on July 1, 2025, which may create greater market confidence and a more transparent and liquid marketplace for shareholders.

Negatives

• The quarterly net loss widened to $(263) thousand in Q3 2025 from $(158) thousand in Q3 2024.
• The nine-month net loss widened to $(950) thousand in 2025 from $(740) thousand in 2024.
• Gross margin decreased to 40.2% in Q3 2025 from 43.7% in Q3 2024, and to 40.6% for the first nine months of 2025 from 41.4% in 2024, primarily due to general cost inflation and tariffs.
• Losses are primarily caused by high research and development costs associated with the push to commercialize the SpinDetect centrifugal drug analyzer.
• Cash and cash equivalents significantly decreased from $1,243,746 at December 31, 2024, to $685,097 at September 30, 2025.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $(578,437).
• Net cash used in investing activities for the nine months ended September 30, 2025, was $(350,156).
• Interest expense increased significantly to $(36,953) in Q3 2025 from $(10,019) in Q3 2024, and to $(87,753) for the nine months ended September 30, 2025, from $(30,226) in 2024.

Risks

• Continued progress toward the commercialization milestones for the SpinDetect centrifugal drug analyzer will depend on securing additional financing.
• General cost inflation and tariffs are negatively impacting the company's gross margins.
• Forward-looking statements involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated.
• Broader applications of the microfluidic technology into adjacent markets will require additional research, licensing, and regulatory clearances.

Future Outlook

The company anticipates a commercial launch of its SpinDetect oral-fluid analyzer, initially for delta-9-THC detection, in 2026, followed by a multi-drug panel release and expansion into other sample types like blood and breath. Development of a combined LX9 breathalyzer + THC SpinDx unit is planned as a next-generation roadside marijuana breath testing system. The company is also exploring broader applications of its microfluidic technology in public health, food safety, and environmental testing, which will require additional research, licensing, and regulatory clearances.

Management Comments

• "We believe our core alcohol detection product line-up continues to be strong."
• "We see our greatest opportunity at the intersection of a growing global demand for rapid drug-of-abuse detection and Lifelocs established expertise in creating rugged, intuitive testing equipment."
• "Prototype SpinDetect analyzers are now traveling to trade shows for customer demonstrations." Dr. Wayne Willkomm, Lifeloc's President and CEO.
• "We are encouraged by early engagement and interest as we move closer to market introduction." Dr. Wayne Willkomm, Lifeloc's President and CEO.
• "Rapid oral-fluid drug testing represents our most immediate and scalable growth opportunity, and we believe SpinDetect can meet this need effectively." Dr. Wayne Willkomm, Lifeloc's President and CEO.
• "Beyond oral-fluid applications, this platform offers a powerful foundation for testing other sample types and analytes." Dr. Wayne Willkomm, Lifeloc's President and CEO.
• "This versatility positions Lifeloc to extend the platform into adjacent markets in public health, food safety, and environmental testing."
• "The scalability and analytical precision of the SpinDetect platform provide a solid foundation for sustained growth across multiple high-impact sectors."

Industry Context

Lifeloc Technologies operates in the breath alcohol and drug testing device market, which is experiencing growing global demand for rapid drug-of-abuse detection. The company's SpinDetect platform aims to address this need with portable, quantitative multi-drug testing, potentially expanding into broader microfluidic applications in public health, food safety, and environmental testing. The shift to OTCID for trading may enhance market confidence and liquidity for shareholders.

Comparison to Industry Standards

• L-series LX9 and LT7 units offer features such as smartphone pairing, wider temperature use ranges, and fast customization, which address previously unmet market needs.
• FC-series devices are certified to modern registration standards, including SAIs AS 3547:2019 for Breath Alcohol Detectors, maintaining their popularity with law enforcement and international organizations.
• The Easycal automated calibration station is highlighted as the only automated calibration available for portable breath alcohol testers, providing a unique competitive advantage.
• The SpinDx system's successful detection of multiple drug classes (delta-9-THC, cocaine, fentanyl, amphetamine, methamphetamine, morphine, MDMA, and benzodiazepines) in laboratory testing, validated against gold-standard liquid chromatography-mass spectrometry (LCMS) testing of human samples at detection limits of approximately 10 ng/ml, demonstrates strong technical performance in drug detection.

Corporate Governance

Stakeholder Impact

• Shareholders: Experienced a wider net loss per share, but potential for future growth from SpinDetect. The move to OTCID may improve market confidence and liquidity. Dilution from option exercise and warrants.
• Employees: Continued R&D focus on SpinDetect suggests ongoing work in product development.
• Customers (Law Enforcement, Workplace, International): Benefit from strong core alcohol detection products and the upcoming SpinDetect drug analyzer, offering advanced testing capabilities.
• Creditors: Increased term loan payable and subordinated debentures payable indicate higher debt levels.

Next Steps

• Improve assay robustness and optimize disk design for SpinDetect to complete analysis within a single disposable cartridge.
• Initiate beta testing of the SpinDetect oral-fluid analyzer focused on delta-9-THC detection.
• Complete final component optimization for SpinDetect under a signed beta-testing agreement.
• Commercial launch of SpinDetect oral-fluid analyzer in 2026, initially for delta-9-THC.
• Subsequent expansion of SpinDetect into additional multi-drug panels and sample types (blood, breath).
• Develop a combined LX9 breathalyzer + THC SpinDx unit as a next-generation roadside marijuana breath testing system.
• Secure additional financing to support continued progress toward SpinDetect milestones.
• Conduct further research, licensing, and regulatory clearances for broader applications of microfluidic technology in public health, food safety, and environmental testing.

Key Dates

Recommendation

While Lifeloc Technologies shows promising innovation with its SpinDetect drug analyzer and reported an 8% increase in quarterly revenue, the widening net losses, declining gross margins due to cost inflation, and significant cash burn are concerning. The explicit need for additional financing to commercialize SpinDetect introduces a notable financial risk. The core alcohol detection business remains strong, providing a stable base. However, the current financial performance and reliance on future financing for growth initiatives suggest a "hold" recommendation. Investors should monitor progress on SpinDetect's commercialization and the company's ability to secure necessary funding, as well as improvements in profitability and cash flow.

Keywords

breath alcohol testing, drug testing devices, SpinDetect, THC detection, oral fluid analyzer, microfluidic technology, law enforcement, workplace safety, LCTC, SEC filing, financial results, Q3 2025, cannabis detection, fentanyl detection